Travoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. The DMF for Travoprost is on file with the US FDA, Canada, India, China, in several EU member states, and in several other countries.
Cayman Chemical's Contract Services group helps companies turn their new drug ideas into reality. Whether for phase I, phase II, phase III, or toxicology studies, we specialize in developing new synthetic routes while providing all the necessary support to ensure regulatory compliance. The Cayman advantage offers the flexibility to support any size project, allowing you to create a customized service to meet your needs. Contact us to learn more about our experience, compliance, low cost, and dedication to customer satisfaction.